IRIS

Di Giambenedetto, S., Fabbiani, M., Colafigli, M., Bracciale, L., D'Ettorre, G., Paoletti, F., et al. (2011). Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study (RAltegravir Simplification for Toxicity or Adverse events, RASTA study). In 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB365)..

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study (RAltegravir Simplification for Toxicity or Adverse events, RASTA study)

Fabbiani M;
2011-01-01
2011
Di Giambenedetto, S., Fabbiani, M., Colafigli, M., Bracciale, L., D'Ettorre, G., Paoletti, F., et al. (2011). Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study (RAltegravir Simplification for Toxicity or Adverse events, RASTA study). In 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB365)..
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1277757
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo